Rapid HIV Test Group O Requirement Endorsed By FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Maintaining FDA's policy of requiring the detection of strain O of the HIV virus outweighs the benefit of having more rapid tests, the agency's Blood Products Advisory Committee agreed at its June 18 meeting in Rockville, Maryland.